Qu Hui, Xie Bao-Dong, Wu Jian, Lv Bo, Chuai Jun-Bo, Li Jian-Zhong, Cai Jun, Wu Hua, Jiang Shu-Lin, Leng Xiao-Ping, Kang Kai
Department of Pediatrics, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Cardiovascular Surgery, The Second Affiliated Hospital of Harbin Medical University, Key Laboratory of Education Ministry for Myocardial Ischemia, Harbin, China.
Stem Cells Int. 2018 Feb 13;2018:4717802. doi: 10.1155/2018/4717802. eCollection 2018.
Engineered heart tissues (EHTs) present a promising alternative to current materials for surgical ventricular restoration (SVR); however, the clinical application remains limited by inadequate vascularization postimplantation. Moreover, a suitable and economic animal model for primary screening is another important issue.
Recently, we used 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride chemistry (EDC) to initiate a strengthened, cytokine-conjugated collagenous platform with a controlled degradation speed. In vitro, the biomaterial exhibited an enhanced mechanical strength maintaining a porous ultrastructure, and the constant release of cytokines promoted the proliferation of seeded human mesenchymal stem cells (hMSCs). In vivo, with the hMSC-seeded, cytokine-immobilized patch (MSCs + GF patch), we performed modified SVR for rats with left ventricular aneurysm postmyocardial infarction (MI). Overall, the rats that underwent modified SVR lost less blood and had lower mortality. After 4 weeks, the rats repaired with this cell-seeded, cytokine-immobilized patch presented preserved cardiac function, beneficial morphology, enhanced cell infiltration, and functional vessel formation compared with the cytokine-free (MSC patch), cell-free (GF patch), or blank controls (EDC patch). Furthermore, the degradable period of the collagen patch in vivo extended up to 3 months after EDC treatment.
EDC may substantially modify collagen scaffold and provide a promising and practical biomaterial for SVR.
工程化心脏组织(EHTs)为目前用于外科心室修复(SVR)的材料提供了一种有前景的替代方案;然而,其临床应用仍受植入后血管化不足的限制。此外,一种合适且经济的用于初步筛选的动物模型是另一个重要问题。
最近,我们使用1-乙基-3-(3-二甲基氨基丙基)碳二亚胺盐酸盐化学法(EDC)构建了一个降解速度可控的、强化的、细胞因子偶联的胶原平台。在体外,该生物材料表现出增强的机械强度并维持多孔超微结构,细胞因子的持续释放促进了接种的人间充质干细胞(hMSCs)的增殖。在体内,我们使用接种了hMSC的、固定有细胞因子的贴片(MSCs + GF贴片)对心肌梗死(MI)后左心室室壁瘤大鼠进行改良SVR。总体而言,接受改良SVR的大鼠失血更少且死亡率更低。4周后,与无细胞因子(MSC贴片)、无细胞(GF贴片)或空白对照(EDC贴片)相比,用这种接种细胞、固定有细胞因子的贴片修复的大鼠心脏功能得以保留,形态良好,细胞浸润增强,且形成了功能性血管。此外,经EDC处理后,胶原贴片在体内的降解期延长至3个月。
EDC可能会显著修饰胶原支架,并为SVR提供一种有前景且实用的生物材料。